论文部分内容阅读
目的探讨硝苯吡啶联合硫酸镁对妊娠期高血压疾病患者血压值、妊娠相关蛋白A(PAPP-A)及血管内皮生长因子(VEGF)的影响。方法以该院2013年3月-2016年3月收治的220例妊娠期高血压疾病患者为研究对象,随机分为观察组和对照组,每组110例。观察组使用硝苯吡啶、硫酸镁联合治疗,对照组单纯使用硫酸镁治疗;比较两组患者的临床疗效及治疗前后血压值、PAPP-A及VEGF变化。结果观察组和对照组的总有效率分别为92.7%和70.9%,差异有统计学意义(P<0.05)。治疗后,两组患者的血压均显著下降,且观察组显著低于对照组(P<0.05)。治疗后,两组患者PAPP-A、VEGF水平显著降低,且观察组显著低于对照组(P<0.05)。两组不良反应率分别为5.5%和6.4%,差异无统计学意义(P>0.05)。观察组并发症发生率显著低于对照组,差异有统计学意义(P<0.05)。结论硫酸镁联合硝苯吡啶能够降低妊娠期高血压疾病患者血清PAPP-A、VEGF水平及血压值,减少并发症发生率,提高疗效,但其降低血清PAPP-A、VEGF水平的机制还有待于进一步研究。
Objective To investigate the effect of nifedipine and magnesium sulfate on blood pressure, pregnancy-associated protein A (PAPP-A) and vascular endothelial growth factor (VEGF) in patients with hypertensive disorder complicating pregnancy. Methods A total of 220 patients with hypertensive disorder complicating pregnancy who were admitted to our hospital from March 2013 to March 2016 were randomly divided into observation group and control group with 110 cases in each group. The observation group was treated with nifedipine and magnesium sulfate, while the control group was treated with magnesium sulfate alone. The clinical efficacy and the changes of PAPP-A and VEGF before and after treatment were compared between the two groups. Results The total effective rate in observation group and control group was 92.7% and 70.9%, respectively, with statistical significance (P <0.05). After treatment, the blood pressure of both groups decreased significantly, and the observation group was significantly lower than the control group (P <0.05). After treatment, the levels of PAPP-A and VEGF were significantly decreased in both groups, and the observation group was significantly lower than the control group (P <0.05). Adverse reactions of the two groups were 5.5% and 6.4%, respectively, with no significant difference (P> 0.05). The incidence of complication in the observation group was significantly lower than that in the control group, the difference was statistically significant (P <0.05). Conclusions Magnesium sulfate combined with nifedipine can reduce serum PAPP-A and VEGF levels and blood pressure in patients with hypertensive disorder complicating pregnancy, reduce the incidence of complications and improve the curative effect. However, the mechanism of lowering serum PAPP-A and VEGF remains to be further research.